Percutaneous balloon mitral valvuloplasty with shockwave lithotripsy for the treatment of calcific mitral valve stenosis

Sami M. Alnasser,Melissa Moey,Noman Ali,Loai Almazroa,Abdul‐Aziz Alshaibi,Samantha Liauw,Mathias Claeys,Geraldine Ong,Neil P. Fam
DOI: https://doi.org/10.1002/ccd.31063
IF: 2.3
2024-05-05
Catheterization and Cardiovascular Interventions
Abstract:Background Calcific mitral stenosis (calcific MS) presents a challenge for surgical treatment and is a contraindication for most contemporary transcatheter mitral valve replacement devices (TMVR), rendering patients with very limited therapeutic options. Aims This study aims to assess the clinical and hemodynamic follow‐up after mitral valve lithotripsy (MVL). Methods All consecutive patients who underwent MVL to treat symptomatic calcific MS at St Michael's Hospital, Toronto, Canada, were included. Patients were deemed unsuitable for mitral surgery or TMVR after heart team assessment. Patients with rheumatic MS or ≥moderate mitral regurgitation (MR) were excluded. The primary endpoint was a reduction in the invasive mitral gradient by ≥50% without significant (≥moderate) MR. Results Fifteen patients underwent MVL between 2021 and 2023 with a mean age of 74 ± 9 years; 53% were female, with a mean STS score of 10% ± 0.1%. Following MVL, there was a reduction in the invasively measured mean trans‐mitral gradient compared to baseline (14 mmHg vs. 6 mmHg; p
cardiac & cardiovascular systems
What problem does this paper attempt to address?